Northern Trust Corp Rain Therapeutics Inc. Transaction History

Northern Trust Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.84 - $1.22 $20,754 - $30,143	24,708 Added 27.11%	115,856 $139,000
Q3 2023 Nov 13, 2023	SELL	$0.82 - $1.42 $29,392 - $50,899	-35,845 Reduced 28.23%	91,148 $78,000
Q2 2023 Aug 11, 2023	BUY	$1.09 - $9.93 $108,347 - $987,051	99,401 Added 360.25%	126,993 $152,000
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $100,201 - $160,813	12,896 Added 87.75%	27,592 $241,000
Q4 2022 Feb 13, 2023	BUY	$5.52 - $8.48 $7,623 - $11,710	1,381 Added 10.37%	14,696 $117,000

Q3 2022 Nov 14, 2022	SELL	$4.75 - $8.01 $5,771 - $9,732	-1,215 Reduced 8.36%	13,315 $65,000
Q2 2022 Aug 12, 2022	SELL	$2.21 - $5.56 $237,119 - $596,554	-107,294 Reduced 88.07%	14,530 $80,000
Q1 2022 May 13, 2022	BUY	$5.07 - $13.68 $252,115 - $680,265	49,727 Added 68.97%	121,824 $618,000
Q4 2021 Feb 08, 2022	BUY	$11.91 - $17.0 $28,631 - $40,868	2,404 Added 3.45%	72,097 $929,000
Q3 2021 Nov 15, 2021	SELL	$13.21 - $20.91 $86,908 - $137,566	-6,579 Reduced 8.63%	69,693 $1.04 Million
Q2 2021 Aug 13, 2021	BUY	$15.08 - $20.3 $1.15 Million - $1.55 Million	76,272 New	76,272 $1.19 Million

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.